Quantitative indicators of TREC and KREC excision circles in malignancies: a prospective cohort study
- Authors: Sultanbaev A.V.1,2, Musin S.I.1, Menshikov K.V.1,2, Sultanbaeva N.I.1, Tuzankina I.A.3,4, Lipatov D.O.2, Menshikova I.A.2, Sultanbaev M.V.2, Kudlay D.A.5,6, Prodeus A.P.7
-
Affiliations:
- Republican Clinical Oncology Dispensary
- Bashkir State Medical University
- Institute of Immunology and Physiology
- Regional Childrens Clinical Hospital
- Sechenov First Moscow State Medical University (Sechenov University)
- State Scientific Center “Institute of Immunology”
- Research Clinical Institute of Childhood
- Issue: Vol 26, No 2 (2024)
- Pages: 132-138
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/260590
- DOI: https://doi.org/10.26442/18151434.2024.2.202679
- ID: 260590
Cite item
Full Text
Abstract
Background. In oncology, of particular interest is the study of the T-cell receptor excision circles (TREC) and the κ-deletion B-cell receptor excision circles (KREC), which are extrachromosomal DNA structures. In many malignancies, the effectiveness of immune checkpoint inhibitors depends on the mutational load of the tumor, which correlates with the formation of specific antitumor immunity. Quantitative indicators of recombination excision circles reflect the occurrence of a different repertoire of T-cell receptors, an integral component in the formation of specific immunity. Understanding the change in quantitative values of TREC and KREC in cancer patients can improve the selection of patients for immunotherapy.
Aim. To determine quantitative indicators of TREC and KREC for immunological evaluation of patients with malignancies.
Materials and methods. The study included 55 healthy individuals and 180 patients with malignancies. Among healthy individuals, 49.1% (27/55) were males and 50.9% (28/55) females. Among patients with malignancies, 20.5% (37/180) were males and 79.5% (143/180) females. The median age in healthy individuals was 36 years [Q1–Q3: 26–58]. The median age in the group of patients with malignancies was 57 years [Q1–Q3: 47.5–67].
Results. In the general population of healthy individuals, the median TREC level was 60.1 [Q1-Q3: 31.3-188.9] and the median KREC level was 256 [Q1-Q3: 149.8-353]. In the general population of patients with malignancies, the median TREC rate was 4.6 [Q1-Q3: 0.9-17.3] and the median KREC was 111.9 [Q1-Q3: 29.3-339.28]. According to the results of the study, we noted statistically significant differences in TREC and KREC indices between all patients with malignancies and healthy individuals (p<0.001, p=0.001). Analysis of TREC and KREC indices in patients with malignancies of various localizations (breast cancer, ovarian cancer, lung cancer, colorectal cancer, skin melanoma, lymphomas) in comparison with healthy individuals statistically significant differences in TREC level were noted (p=0.001, p<0.001). When analyzing the KREC level in the studied groups, statistically significant differences in patients with ovarian malignancies (p<0.001), lymphoma (p<0.001), colorectal cancer (p=0.001) and melanoma (p=0.039) in comparison with healthy individuals were obtained. When comparing groups pairwise, it was found that TREC level in patients with malignancies in the age group of 25–44 years was significantly higher than in the age group of 45–60 years (p=0.03); TREC level in the age group of 25–44 years was significantly higher than in the age group of persons over 60 years (p<0.001); TREC level in the age group of 45–60 years was significantly higher than in the age group over 60 years (p<0.001). Statistically significant differences of KREC level in the studied patients with malignancies depending on the age group were not established (p=0.16), there were no age differences of groups by KREC level.
Conclusion. The results demonstrate a significant decrease in TREC and KREC levels in patients with malignancies compared to healthy individuals. The study of TREC and KREC excision circles in peripheral blood is one of the promising approaches for the immunological evaluation of cancer patients.
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
Alexander V. Sultanbaev
Republican Clinical Oncology Dispensary; Bashkir State Medical University
Author for correspondence.
Email: sultanbaevav@onkorb.ru
ORCID iD: 0000-0003-0996-5995
Cand. Sci. (Med.), Republican Clinical Oncology Dispensary, Bashkir State Medical University
Russian Federation, Ufa; UfaShamil I. Musin
Republican Clinical Oncology Dispensary
Email: musin_shamil@mail.ru
ORCID iD: 0000-0003-1185-977X
Cand. Sci. (Med.)
Russian Federation, UfaKonstantin V. Menshikov
Republican Clinical Oncology Dispensary; Bashkir State Medical University
Email: kmenshikov80@bk.ru
ORCID iD: 0000-0003-3734-2779
Cand. Sci. (Med.), Republican Clinical Oncology Dispensary, Bashkir State Medical University
Russian Federation, Ufa; UfaNadezda I. Sultanbaeva
Republican Clinical Oncology Dispensary
Email: nd.sultan@rambler.ru
ORCID iD: 0000-0001-5926-0446
oncologist
Russian Federation, UfaIrina A. Tuzankina
Institute of Immunology and Physiology; Regional Childrens Clinical Hospital
Email: ituzan@yandex.ru
ORCID iD: 0000-0001-7496-0950
D. Sci. (Med.), Prof., Institute of Immunology and Physiology, Regional Childrens Clinical Hospital
Russian Federation, Yekaterinburg; YekaterinburgDanila O. Lipatov
Bashkir State Medical University
Email: lipatov911@gmail.com
ORCID iD: 0000-0002-3193-9008
Student
Russian Federation, UfaIrina A. Menshikova
Bashkir State Medical University
Email: i-menshikova@bk.ru
ORCID iD: 0000-0002-8665-8895
Cand. Sci. (Med.), Assoc. Prof.
Russian Federation, UfaMikhail V. Sultanbaev
Bashkir State Medical University
Email: sultanbaevav@onkorb.ru
ORCID iD: 0000-0002-2222-4940
Cand. Sci. (Chem.)
Russian Federation, UfaDmitry A. Kudlay
Sechenov First Moscow State Medical University (Sechenov University); State Scientific Center “Institute of Immunology”
Email: sultanbaevav@onkorb.ru
ORCID iD: 0000-0003-1878-4467
D. Sci. (Med.), Corr. Member RAS, Sechenov First Moscow State Medical University (Sechenov University), State Scientific Center “Institute of Immunology”
Russian Federation, Moscow; MoscowAndrey P. Prodeus
Research Clinical Institute of Childhood
Email: sultanbaevav@onkorb.ru
ORCID iD: 0000-0001-5435-1859
D. Sci. (Med.), Prof.
Russian Federation, MoscowReferences
- Schultze JL, Mass E, Schlitzer A. Emerging principles in myelopoiesis at homeostasis and during infection and inflammation. Immunity. 2019;50:288-301.
- Bone G, Lauder I. Cellular immunity, peripheral blood lymphocyte count and pathological staging of tumours in the gastrointestinal tract. Br J Cancer. 1974;30(3):215-21. doi: 10.1038/bjc.1974.184
- Borg C, Ray-Coquard I, Philip I, et al. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer. 2004;101:2675-80. doi: 10.1002/cncr.20688
- Ray-Coquard I, Borg C, Bachelot T, et al. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer. 2003;88(2):181-6. doi: 10.1038/sj.bjc.6600724
- Peron J, Cropet C, Tredan O, et al. CD4 lymphopenia to identify end-of-life metastatic cancer patients. Eur J Cancer. 2013;49:1080-9. doi: 10.1016/j.ejca.2012.11.003
- Ray-Coquard I, Cropet C, Van Glabbeke M, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383-91. doi: 10.1158/0008-5472.CAN-08-3845
- Trédan O, Manuel M, Clapisson G, et al. Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. Eur J Cancer. 2013;49(7):1673-82. doi: 10.1016/j.ejca.2012.11.028
- Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345-59. doi: 10.1038/s41568-021-00347-z
- Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253-68. doi: 10.1038/nri3175
- Allen BM, Hiam KJ, Burnett CE, et al. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat Med. 2020;26(7):1125-34. doi: 10.1038/s41591-020-0892-6
- Wu WC, Sun HW, Chen HT, et al. Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. Proc Natl Acad Sci U S A. 2014;111(11):4221-6. doi: 10.1073/pnas.1320753111
- Jaillon S, Ponzetta A, Di Mitri D, et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485-503. doi: 10.1038/s41568-020-0281-y
- Shaul ME, Fridlender ZG. Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601-20. doi: 10.1038/s41571-019-0222-4
- Templeton AJ, McNamara MG, Šeruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi: 10.1093/jnci/dju124
- Binnewies M, Mujal AM, Pollack JL, et al. Unleashing Type-2 Dendritic Cells to Drive Protective Antitumor CD4+ T Cell Immunity. Cell. 2019;177(3):556-71.e16. doi: 10.1016/j.cell.2019.02.005
- Failli A, Legitimo A, Orsini G, et al. Numerical defect of circulating dendritic cell subsets and defective dendritic cell generation from monocytes of patients with advanced melanoma. Cancer Lett. 2013;337(2):184-92. doi: 10.1016/j.canlet.2013.05.013
- Султанбаев А.В., Мусин Ш.И., Меньшиков К.В., и др. Прогностическое значение эксцизионных колец KREC и TREC при злокачественных новообразованиях. Материалы V юбилейного Международного Форума онкологии и радиологии. Мoсква, 19–23 сентября 2022 г.; с. 191 [Sultanbaiev AV, Musin ShI, Men’shikov KV, et al. Prognosticheskoe znachenie ekstsizionnykh kolets KREC i TREC Pri zlokachestvennykh novoobrazovaniiakh. Materialy V iubileinogo Mezhdunarodnogo Foruma onkologii i radiologii. Moscow, 19–23 sentyabria 2022 g.; p. 191 (in Russian)].
- Давыдова Н.В., Продеус А.П., Образцов И.В., и др. Референсные значения концентрации TREC и KREC у взрослых. Врач. 2021;32(6):21-8 [Davydova NV, Prodeus AP, Obraztsov IV, et al. Reference values for TREC and KREC concentrations in adults. Vrach. 2021;32(6):21-8 (in Russian)]. doi: 10.29296/25877305-2021-06-05
- Корсунский И.А., Кудлай Д.А., Продеус А.П., и др. Неонатальный скрининг на первичные иммунодефицитные состояния и Т-/В-клеточные лимфопении как основа формирования групп риска детей с врожденными патологиями. Педиатрия им. Г.Н. Сперанского. 2020;99(2):8-15 [Korsunsky IA, Kudlay DA, Prodeus AP. et al. Neonatal screening for primary immunodeficiency and Т-/B-cell lymphopenia as the basis for the formation of risk groups for children with congenital pathologies. Pediatria n.a. GN Speransky. 2020;99(2):8-15 (in Russian)].
- Дерябина С.С., Тузанкина И.А., Черемохин Д.А., и др. Пилотный проект неонатального скрининга на первичные иммунодефициты в Свердловской области – от скрининга к диспансеризации. Педиатрия им. Г.Н. Сперанского. 2023;102(3):95-106 [Deryabina SS, Tuzankina IA, Cheremokhin DA, et al. Pilot regional project of neonatal screening for primary immunodeficiencies in Sverdlovsk Oblast of Russia. From screening to prophylactic medical checkup. Pediatria n.a. GN Speransky. 2023;102(3):95-106 (in Russian)]. doi: 10.24110/0031-403X-2023-102-3-95-106
- Корсунский И.А., Продеус А.П., Румянцев А.Г., и др. Скрининг новорожденных на первичные иммунодефициты и группу риска иммунорегуляторных расстройств, требующих диспансерного наблюдения. Педиатрия. 2019;98(3):49-54 [Korsunsky IA, Prodeus AP, Rumyantsev AG, et al. Screening of newborns for primary immunodeficiencies and risk groups for immunoregulatory disorders requiring follow-up. Pediatria. 2019;98(3):49-54 (in Russian)]. doi: 10.24110/0031-403X-2019-98-3-49-54
- Drylewicz J, Vrisekoop N, Mugwagwa T, et al. Reconciling Longitudinal Naive T-Cell and TREC Dynamics during HIV-1 Infection. PLoS One. 2016;11(3):e0152513. doi: 10.1371/journal.pone.0152513
- Mikhael NL, Elsorady M. Clinical significance of T cell receptor excision circle (TREC) quantitation after allogenic HSCT. Blood Res. 2019;54(4):274-81. doi: 10.5045/br.2019.54.4.274
- Morgun A, Shulzhenko N, Socorro-Silva A, et al. T cell receptor excision circles (TRECs) in relation to acute cardiac allograft rejection. J Clin Immunol. 2004;24(6):612-6. doi: 10.1007/s10875-004-6246-1
- Söderström A, Vonlanthen S, Jönsson-Videsäter K, et al. T cell receptor excision circles are potential predictors of survival in adult allogeneic hematopoietic stem cell transplantation recipients with acute myeloid leukemia. Front Immunol. 2022;13:954716. doi: 10.3389/fimmu.2022.954716
- Savchenko AA, Tikhonova E, Kudryavtsev I, et al. TREC/KREC Levels and T and B Lymphocyte Subpopulations in COVID-19 Patients at Different Stages of the Disease. Viruses. 2022;14(3):646. doi: 10.3390/v14030646
- Козлов В.А., Тихонова Е.П., Савченко А.А., и др. Клиническая иммунология. Практическое пособие для инфекционистов. Красноярск: Поликор, 2021 [Kozlov VA, Tikhonova EP, Savchenko AA, et al. Klinicheskaia immunologiia. Prakticheskoe posobie dlia infektsionistov. Krasnoiarsk: Polikor, 2021 (in Russian)]. doi: 10.17513/np.518
- Образцов И.В., Гордукова М.А., Цветкова Е.В., и др. Эксцизионные кольца V(D)J рекомбинации B- и T-клеток как показатели иммунологической реконституции у детей с острым лимфобластным лейкозом. Вопросы гематологии / онкологии и иммунопатологии в педиатрии. 2016;15(4):42-50 [Obraztsov IV, Gordukova MA. Tsvetkova EV, et al. B- and T-cell V(D)J-recombination excision circles as indicators of immunological reconstitution in children with acute lymphoblastic leukemia. Pediatric Haematology / Oncology and Immunopathology. 2016;5(4):42-50 (in Russian)]. doi: 10.20953/1726-1708-2016-4-42-50
- Образцов И.В., Гордукова М.А., Северина Н.А., и др. Эксцизионные кольца V(D)J-рекомбинации B- и T-клеток как прогностический маркер при В-клеточном хроническом лимфолейкозе. Клиническая онкогематология. 2017;10(2):131-40 [Obraztsov IV, Gordukova MA, Severina NA, et al. V(D)J Recombination Excision Circles of B- and T-cells as Prognostic Marker in B-Cell Chronic Lymphocytic Leukemia. Clinical Oncohematology. 2017;10(2):131-40 (in Russian)]. doi: 10.21320/2500-2139-2017-10-2-131-140
- Motta M, Chiarini M, Ghidini C, et al. Quantification of newly produced B and T lymphocytes in untreated chronic lymphocytic leukemia patients. J Transl Med. 201;8:111. doi: 10.1186/1479-5876-8-111
- Kwok JSY, Cheung SKF, Ho JCY, et al. Establishing Simultaneous T Cell Receptor Excision Circles (TREC) and K-Deleting Recombination Excision Circles (KREC) Quantification Assays and Laboratory Reference Intervals in Healthy Individuals of Different Age Groups in Hong Kong. Front Immunol. 2020;11:1411. DOI:10.3389/ fimmu.2020.01411
- Sultanbaev AV, Musin S, Menshikov K, et al. 99P Quantitative indicators of TREC and KREC excision rings in malignant neoplasms. ESMO Open. 2023;8(1-Suppl. 2):100957. doi: 10.1016/j.esmoop.2023.100957